Evaluation of the immunogenicity of liposome encapsulated HVR1 and NS3 regions of genotype 3 HCV, either singly or in combination

Table 2 Immunogen formulation and doses

Immunogen	Dosage	Adjuvant used
	25 μg peptide + 5 μg corresponding DNA	cadB
HVR1 variant1	50 μg peptide + 5 μg corresponding DNA	cadB
	50 μg peptide + 1 μg pNS3
	25 μg peptide + 5 μg corresponding DNA	cadB
HVR1 variant2	50 μg peptide + 5 μg corresponding DNA	cadB
	50 μg peptide + 1 μg pNS3	cadB
	25 μg peptide + 5 μg corresponding DNA
HVR1 variant3	50 μg peptide + 5 μg corresponding DNA
	50 μg peptide + 1 μg pNS3	cadB
	25 μg peptide + 5 μg corresponding DNA	cadB
HVR1 variant4	50 μg peptide + 5 μg corresponding DNA	cadB
	50 μg peptide + 1 μg pNS3
	Peptide pool + 5 μg DNA corresponding to each peptide	cadB
	Peptide pool + 1 μg pNS3	cadB
HVR1 variant pool (25 μg each peptide)	pool + 1 μg pNS3	Aluminium hydroxide
	pool + 1 μg pNS3	no adjuvant
	Peptide Pool	cadB
	Peptide Pool	Aluminium hydroxide
	Peptide Pool	no adjuvant
HVR1 variant tetramer	Tetramer 10 μg	aluminium hydroxide
	Tetramer 10 μg	cadB
HVR variant tetramer + pNS3	10 μg tetramer + 1 μg pNS3	aluminium hydroxide
	10 μg tetramer + 1 μg pNS3	cadB
	1 μg pNS3	cadB
	5 μg pNS3	cadB
NS3	1 μg pNS3 + 5 μg corresponding DNA	cadB
	1 μg pNS3	no adjuvant

ISSN: 1743-422X